Both firms will also assess the integration of Trice technologies with Bioventus’ current and future peripheral nerve stimulation (PNS) offerings to boost the adoption of both companies’ products

Orthopedic

Trice Medical develops and commercialises minimally invasive technologies for sports medicine and orthopaedic surgical procedures. (Credit: Andersonvr from Pixabay)

Active healing solutions provider Bioventus has made a strategic investment in minimally invasive technologies developer Trice Medical.

Trice Medical is engaged in the development and commercialisation of minimally invasive technologies for sports medicine and orthopaedic surgical procedures.

Bioventus will secure exclusive sales and distribution rights to Trice’s products outside of the US, in conjunction with the company leading the Series D funding round.

Bioventus has also agreed to enter into a co-development arrangement with Trice to assess the integration of Trice technologies with Bioventus’ current and future peripheral nerve stimulation (PNS) offerings, including StimRouter and TalisMann, to boost the adoption of both companies’ products.

Bioventus business development and strategy senior vice president Chris Yamamoto said: “Trice’s established and growing presence in sports medicine and orthopaedics is directly aligned with our strategy of expanding our offerings across these core Bioventus call points.

“Our investment will not only fund the ongoing growth of Trice, but also is expected to allow both companies to further validate the merits of a combination.”

The latest investment allowed Yamamoto to join as the board member of Trice.

Established in 2011, Trice integrates its handheld arthroscope and portable ultrasound visualisation technologies with the firm’s surgical devices to treat a range of sports medicine and orthopaedic conditions, including tendinopathy, planter fasciitis and carpel tunnel.

Trice devices are said to enhance patient recovery time, reduce pain, minimise scarring and move surgical procedures out of higher-cost points of care.

Lasrt month, Bioventus agreed to acquire ultrasonic medical devices provider Misonix in a cash-and-stock transaction valued at up to $518m.